Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)

To evaluate whether subjects with diabetes hospitalized for Coronavirus disease-19 (Covid-19) represent a subgroup of patients with high-risk clinical features compared to patients with diabetes without Covid-19. In this case-control study 79 patients with type 2 diabetes out of 354 adults hospitali...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes research and clinical practice 2020-11, Vol.169, p.108454-108454, Article 108454
Hauptverfasser: Maddaloni, Ernesto, D'Onofrio, Luca, Alessandri, Francesco, Mignogna, Carmen, Leto, Gaetano, Coraggio, Lucia, Sterpetti, Sara, Pascarella, Giuseppe, Mezzaroma, Ivano, Lichtner, Miriam, Pozzilli, Paolo, Agrò, Felice Eugenio, Rocco, Monica, Pugliese, Francesco, Mastroianni, Claudio Maria, Buzzetti, Raffaella
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To evaluate whether subjects with diabetes hospitalized for Coronavirus disease-19 (Covid-19) represent a subgroup of patients with high-risk clinical features compared to patients with diabetes without Covid-19. In this case-control study 79 patients with type 2 diabetes out of 354 adults hospitalized for Covid-19 and 158 controls with type 2 diabetes but without Covid-19, matched for age and gender, were enrolled. Medical history and concomitant therapies were retrieved from medical charts and compared between cases and controls, controlling for confounders. Fully-adjusted multivariate logistic regression model showed that previous CVD history did not differ between patients with and without Covid-19 (odds ratio 1.40, 95% confidence interval [CI]: 0.59–3.32, p = 0.45). A higher prevalence of chronic obstructive pulmonary disease (COPD) (OR 3.72, 95%CI: 1.42–9.72, p = 0.007) and of chronic kidney disease (CKD) (OR 3.08, 95%CI: 1.18–8.06, p = 0.022) and a lower prevalence of ever smokers (OR 0.30, 95%CI: 0.13–0.67, p = 0.003), of users of lipid lowering agents (OR 0.26, 95%CI: 0.12–0.54, p 
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2020.108454